Considering the Logistics of Weight-Loss Drug Coverage

With the FDA approving select diabetes medication for obesity treatment, employers need to assess how their health plans may be impacted. Demand for weight-loss medication has skyrocketed in recent years, and the decision of whether employers should offer coverage is complicated.

In a recent HR Dive article, Greg Puig shared employers are keeping a close eye on how GLP-1 drugs will be dispersed in the market. He notes that potential cardiovascular benefits of Wegovy are intriguing, however, future treatment plans with the drug remain unclear. Not to mention, many employers are at the mercy of waiting for insurance carriers to make coverage decisions.

“Do people have to be on this forever? Do they gain the weight right back if they come off of it? What are the long-term consequences if they take it for a long time?” Puig said.

Interested in learning more? Check out the full article here.